Phase 3 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with CLL (Chronic Lymphocytic Leukaemia) or SLL (Small Lymphocytic Lymphoma) according to recognised international guidelines, and whose condition has reached a point where treatment is needed
• People who have measurable signs of the disease that can be tracked during the trial
• People with a general health and activity level rated as fairly good to fully active (confirm with trial site)
• People whose heart rhythm test (ECG) shows a specific electrical interval within an acceptable range — no longer than 450 milliseconds for males or 470 milliseconds for females
• People whose bone marrow is functioning well enough without needing additional medical support
• People whose liver, kidneys, and blood clotting function are all within acceptable levels
• People of childbearing potential, and their partners, who are willing to use effective contraception throughout the treatment period and for at least three months after the last dose; male participants must also avoid sperm donation from the first dose until three months after the last dose
• Female participants of childbearing potential who have had a negative blood pregnancy test within 14 days before the first dose
• People who are able to understand and willingly sign a consent form approved by an Ethics Committee before any study procedures begin
• People who are willing and able to attend all required study visits and follow-up appointments

Who may not be able to join:

• People who have previously received any treatment specifically for CLL or SLL
• People who have not fully recovered from a previous surgery, or who have had major surgery within 28 days before the first dose, or minor surgery (other than a biopsy) within 14 days before the first dose
• People who have had a significant heart or cardiovascular condition within the six months before joining the trial
• People with a history of serious kidney, neurological, psychiatric, lung, hormonal, metabolic, immune, heart, or liver disease that could be made worse by participating in the trial (as assessed by the study doctor)
• People who need to take warfarin or other blood-thinning medications, or who have experienced active bleeding within two months before joining the trial
• People who are known to have had an allergic reaction to the study drug or similar medicines
• People who are pregnant, breastfeeding, or expected to become pregnant during the trial or within three months after the last dose
• People who have had another active cancer (other than CLL or SLL) within the three years before joining the trial
• People who have a condition affecting how the body absorbs food or medication through the digestive system, or another condition that makes taking oral medication unsuitable
• People with other significant uncontrolled medical symptoms or conditions
• People with an active autoimmune disease or connective tissue disease
• People whom the study doctor considers unsuitable for the trial for any other reason

Important: Always verify eligibility with the trial site directly before applying.